# SURO Capital

Type: Company (SSSS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/suro-capital
Canonical HTML page: https://getbiobrief.com/entity/suro-capital

## Timeline

- **2026-03-17**: Wall Street Zen Downgrade — SABS and SSSS both receive Sell ratings from Wall Street Zen.
- **2025-Q4**: SAB-142 Clinical Progress — SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
- **2025**: Strategic Pivot — Company shifts focus from infectious diseases to immunology and chronic conditions.

## Recent coverage (2 stories)

### SAB Biotherapeutics Downgraded to Sell Amid Shifting Biotech Sentiment
2026-03-17 06:51:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.
Full story: https://getbiobrief.com/story/sab-biotherapeutics-downgraded-sell-wall-street-zen

### Shoulder Innovations Surges 65% as MedTech Disruption Accelerates
2026-03-12 01:02:01 · Sentiment: Positive · Impact: 6/10 · Sources: 5

Shoulder Innovations reported a record Q4 2025 with $14.4 million in revenue, representing a 65% year-over-year increase. The company's growth is significantly outpacing legacy orthopedic incumbents, fueled by rapid surgeon adoption of its specialized arthroplasty platform.
Full story: https://getbiobrief.com/story/shoulder-innovations-q4-earnings-medtech-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.